Cure8 research brief
Noninfectious skin lesions can occur during ustekinumab treatment for Crohn's disease and may require dermatology care; patients with prior anti-TNF–induced skin reactions appear at higher risk for psoriasiform eruptions.
Adults with Crohn's disease on ustekinumab, clinicians managing biologic therapy, and patients with a history of anti-TNF–related skin reactions
This paper examined 32 adult CD patients from seven centers who developed significant, noninfectious skin lesions while on ustekinumab and required dermatology assessment. The most frequent lesion types were psoriasiform (40%), eczematous (31%), and acneiform (25%), most often affecting the face and trunk.
Topical treatments led to improvement for many patients; ustekinumab was stopped in 25% of cases. Prior anti-TNF–related skin reactions were associated with increased odds of psoriasiform eruptions on ustekinumab.
Retrospective multicenter design; cases were those requiring dermatology assessment so milder events may be undercounted. Associations reported do not establish causation.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Dose increases are common during IBD maintenance and vary a lot by drug and patient profile. Knowing which treatments and patient factors are linked to escalation can help patients and clinicians plan monitoring and...
Patients with moderate-to-severe Crohn's disease who do not respond to anti-TNF drugs have limited options. This study suggests combining ustekinumab with upadacitinib may improve endoscopic healing versus either drug...
A single‑patient report suggests guselkumab (IL‑23 inhibitor) may control both refractory pyoderma gangrenosum and coexisting Crohn disease when several prior treatments failed.
